
Sign up to save your podcasts
Or
David Barmam, founder and CEO of Emendio Biotherapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Emendo is working to evolve traditional CRISPR tools and create new nucleases customized to any genetic disease.
5
77 ratings
David Barmam, founder and CEO of Emendio Biotherapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Emendo is working to evolve traditional CRISPR tools and create new nucleases customized to any genetic disease.
1,040 Listeners
31 Listeners
274 Listeners
309 Listeners
331 Listeners
394 Listeners
122 Listeners
318 Listeners
198 Listeners
84 Listeners
88 Listeners
428 Listeners
147 Listeners
18 Listeners
84 Listeners